As a result, more extensive clinical trials are needed to verify the efficacy of other SGLT2 inhibitors in the management of HF and T2DM as well as the benefits and drawbacks of their use concerning the contraindications and negative effects they encourage. This evidence concerns the gene SLC5A2 and hydrops fetalis.